Durable response rates with talimogene laherparepvec or granulocyte-macrophage colony-stimulating factor are associated with additional clinical benefits in patients with stage IIIB-IVM1a melanoma in the OPTiM trial
Harrington K. et al, (2016), BRITISH JOURNAL OF DERMATOLOGY, 175, 73 - 73
Erratum to: Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis.
Findlay JM. et al, (2016), Dig Dis Sci, 61
Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Middleton MR. et al, (2016), Cancer Med, 5, 1436 - 1443
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J. et al, (2016), Targeted oncology, 11, 401 - 415
Distinct myeloid progenitor differentiation pathways identified through single cell RNA sequencing
Nerlov C. et al, (2016), Nature Immunology
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
Eyre TA. et al, (2016), Br J Haematol, 173, 896 - 904
RUXOLITINIB COMPARED WITH BEST AVAILABLE THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA PATIENTS RESISTANT OR INTOLERANT TO HYDROXYCARBAMIDE IN MAJIC - AN INVESTIGATOR LEAD RANDOMIZED TRIAL
Harrison C. et al, (2016), HAEMATOLOGICA, 101, 97 - 97
SINGLE-CELL PROFILING OF HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITORS IDENTIFIES DISTINCT MEGAKARYOCYTE AND ERYTHROID DIFFERENTIATION PATHWAYS
Psaila B. et al, (2016), HAEMATOLOGICA, 101, 21 - 21
A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.
Armand P. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) A phase 2 study.
Younes A. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).
Plummer ER. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
Real-world overall survival in advanced melanoma from the IMAGE study.
Middleton MR. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma
Middleton MR. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
Mateo J. et al, (2016), Targeted Oncology
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE. and Kennedy RD., (2016), Oncologist, 21, 586 - 593
PREFERENCE-BASED UTILITIES FOR ADJUVANT MELANOMA IN THE UNITED KINGDOM AND AUSTRALIA
Middleton M. et al, (2016), VALUE IN HEALTH, 19, A157 - A157
Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.
Eyre TA. et al, (2016), Br J Haematol, 173, 487 - 491
Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma
Eyre TA. et al, (2016), BRITISH JOURNAL OF HAEMATOLOGY, 173, 487 - 491
TREATMENT PATTERNS AMONG ADVANCED MELANOMA PATIENTS IN EUROPE
Sheahan K. et al, (2016), VALUE IN HEALTH, 19, A162 - A162
Durable response of spinal chordoma to combined inhibition of IGF-1R and EGFR
Macaulay V. et al, (2016), Frontiers in Oncology